Properties

GHRP 2 5MG

Sequence: D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys
Molecular Formula: C45H55N,06
Molecular Weight: 817.9749 g/mol
PubChem CID: 6918245
CAS Number: 158861-67-7
Code Names: KP-102, GPA-748, WAY-GPA-748
Total Amount of the Active Ingredient: 5mg (1 vial)
Shelf Life: 36 months

Uncompromising Quality Assurance for GHRP-2

At Triggered Brand, we are dedicated to providing researchers with high-purity peptides like GHRP 2 that meet the strictest quality standards. Products listed on our site are available in vials and undergo a rigorous quality control process to ensure reliability and consistency for your research.

1. Receipt and Inspection: Upon receiving GHRP 2 5mg peptides from our trusted supplier network, we perform a preliminary quality check to ensure the product meets baseline specifications.
2. Purity and Assay Testing: Before products are listed for sale, they undergo third-party purity testing to confirm the percentage of the active compound and assay testing to verify the compound’s concentration.
   • Purity Testing: Determines the level of impurities or contaminants in the peptide, ensuring it meets research-grade standards.
   • Assay Testing: Confirms the compound’s chemical composition and potency, verifying its suitability for experimental use.
3. Testing Methods: Our testing partners use advanced analytical techniques, including:
   • High-Performance Liquid Chromatography (HPLC): Analyzes purity by separating and quantifying individual components in the peptide.
   • Mass Spectrometry (MS): Identifies the molecular structure and verifies the peptide’s identity.
   • Fourier Transform Infrared Spectroscopy (FTIR): Confirms the peptide’s chemical bonds and functional groups.
   • Nuclear Magnetic Resonance (NMR): Provides detailed structural analysis of the peptide.
4. Approval for Sale: After these tests return positive results, we list GHRP 2 5mg peptides in vials on our site for purchase. This ensures you receive validated research-grade products that you can trust for your experiments. Lab tests are occasionally published on the website.

Scientific literature

Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN

Abstract
Pralmorelin [GPA 748, GHRP-2, growth hormone-releasing peptide 2, KP-102 D, KP 102 LN] is an orally active, synthetic growth hormone-releasing peptide from a series of compounds that were developed by Polygen in Germany and Tulane University in the US. Researchers at Tulane University led by Dr Cyril Bowers synthesised a series of small highly active peptides ranging in size from 3-5 amino acids or partial peptides that were suitable for a variety of administration formats (subcutaneous, buccal, oral, depot). These peptides mimic the actions of ghrelin, a 28 amino acid octanoyl peptide that regulates the release of growth hormone (GH), and may play an important role in bone and muscle growth, food intake and possibly improve recovery from injury. The use of pralmorelin as a diagnostic agent for GH deficiency is based on its ability to markedly increase plasma levels of GH in healthy subjects irrespectively of gender, obesity or age. However, in patients with GH deficiency, the effect of pralmorelin on GH levels is significantly lower compared with healthy controls. Analysis of the receiver-operating characteristics curve provided the cut-off threshold value for the GH peak of 15.0 micro g/L for the identification of patients with GH deficiency from those of healthy controls. Kaken acquired worldwide manufacturing and marketing rights to pralmorelin, and then sublicensed it to Wyeth (formerly American Home Products) for the US and Canada. Kaken retains rights to pralmorelin in Japan. On 11 March 2002 American Home Products changed its name and the names of its subsidiaries Wyeth-Ayerst and Wyeth Lederle to Wyeth. Kaken also granted exclusive sublicense options in Africa, Australia, Europe, Latin America and New Zealand to unspecified partners. Pralmorelin as KP-102 D [KP-102D] is currently awaiting approval in Japan as a diagnostic agent for hypothalamo-pituitary function. It is planned to be launched in Japan for this indication in 2004. Pralmorelin is also undergoing phase II clinical trials with Kaken in Japan for short stature (pituitary dwarfism) as KP-102 LN [KP-102LN]. Its launch for the treatment of short stature is planned for 2009 (Kaken, Annual Report 2003). The agent was undergoing phase II trials in the US for the treatment of GH deficiency with Wyeth; however, it appears that its development was discontinued. Tulane University was granted a US Patent (6,468,974 issued in October 2002), as well as patent protection in Europe and other countries for a series of synthesised GH-releasing peptides.

Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide

Abstract
KP-102 (D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide dihydrochloride, growth hormone-releasing peptide-2, GHRP 2, pralmorelin, CAS 158861-67-7), is a potent synthetic growth hormone (GH) secretagogue. In the present study, the pharmacological characteristics of the GH-releasing property of KP-102 were investigated by means of in vivo and in vitro experiments. In conscious rats, the GH-releasing activity of KP-102 was more potent than that of exogenously injected GH-releasing hormone (GHRH). Under pentobarbital anesthesia in which endogenous somatostatin secretion is known to be decreased, KP-102 and GHRH, both showed an almost equivalent GH-releasing potency, which was also similar to that of KP-102 in conscious rats. Besides, KP-102 showed GH-releasing activity in conscious dogs as well, while GHRH failed to increase serum GH levels in conscious dogs. These findings suggest that the GH-releasing activity of KP-102 was less sensitive to GH suppression by endogenous somatostatin as compared with that of GHRH. The GH-releasing activity of KP-102 was completely absent in hypophysectomized rats, but present in median eminence-lesioned rats in which secreted GH amounts were significantly less than those normal rats, indicating necessity of the median eminence (endogenous GHRH) to exert the full activity of KP-102 in GH stimulation. KP-102 directly stimulated GH secretion from cultured rat anterior pituitary cells, although the GH-releasing potency of KP-102 was significantly weaker than that of GHRH in vitro. In conscious rats, KP-102 stimulated the secretion of both adrenocorticotrophic hormone (ACTH) and corticosterone, but not of prolactin. Three weeks administration of KP-102 showed growth-accelerating effect, a slight increase of body weight and wet weight of some organs in both normal and monosodium glutamate (MSG)-treated rats. These results suggest that KP-102 showed specific GH-releasing activity apart from slight ACTH secretion, and that the GH-releasing activity was stable in comparison with that of exogenously injected GHRH.

GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans

Abstract
Studies with chronic GHRP2 or GHRH administration were performed to demonstrate and better understand the interrelationships between GHRP-2, GHRH and SRIF. Normal younger and older men and women received chronic GHRP-2, GHRH or GHRP-2 + GHRH for 7-30 days. It was demonstrated that chronic administration of either GHRP-2 or GHRH could convert an additive GHRP-2 + GHRH GH response to a synergistic one. In addition, the type of synergistic response induced by chronic GHRP-2 versus GHRH was different. Whether the GH response becomes desensitized during chronic administration depends in part on the dosage and frequency of administration. The potential to learn more about the in vivo actions of GHRP relative to the regulation of GH secretion is underscored by studying the GH responses to GHRP-2, GHRH and GHRP-2 + GHRH.

GHRP2: Dosing and Mixing for Research

Understanding the Format: Vial

GHRP2 is available in a 5mg, these are designed for flexibility in research studies requiring precise preparation and mixing. These formats allow researchers to control mixing solutions and customize protocols according to their study needs.

Mixing GHRP 2 Vials

Proper preparation ensures research accuracy and consistency. Researchers typically use one of the following solutions for mixing:

• Sterile Water for Injection:
  Preferred for single-use applications, sterile water ensures purity and minimizes contamination risks. It’s commonly used in studies requiring a single administration.

• Bacteriostatic Water (BAC Water):
  Containing 0.9% benzyl alcohol, BAC water helps prevent bacterial growth, making it ideal for studies requiring multiple administrations over several days or weeks. Researchers value its stability for extended research. BAC water is included as a gift with any peptide vial purchase.

Understanding Dosing for GHRP-2

When conducting research with GHRP2 5mg Peptide Vial, it is crucial to recognize that dosing parameters vary based on the specific objectives and design of each research study. Research compounds, including GHRP-2, are intended strictly for in vitro testing and laboratory experimentation purposes and are not approved for human consumption.

In accordance with legal and regulatory guidelines, we cannot provide dosing guidance or recommendations for GHRP-2 5mg Peptide Vials. Providing such advice would violate compliance laws, as it could be interpreted as prescribing usage for research studies.

This product is not a drug, food, or cosmetic and must not be introduced into humans or animals under any circumstances. It should only be handled by licensed, qualified professionals in a controlled research environment.

For information regarding dosing, researchers are encouraged to consult peer-reviewed studies or other reputable scientific sources relevant to their field of study.

Fast Shipping in the USA and Canada

USA – Delivery to All 50 States

Order GHRP 2 5MG vials online and enjoy fast, reliable delivery across the USA. Whether you’re in New York, California, or Texas, we ensure your research peptides arrive quickly and securely. Most orders are processed in less than 24 hours and received within 2–5 business days. Shop now to experience the best in quality and service!

Canada – Quick Shipping Nationwide

Shop GHRP 2 5MG vials online with delivery to all provinces and territories in Canada, including Toronto, Vancouver, Montreal, and Calgary. With fast shipping and secure packaging, you can trust us to provide premium research peptides to your doorstep in 5-10 business days. Buy today for exceptional service and quality!

Disclaimer

The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.

Note: In some cases wherein the assigned top colors are out of stock, a different top color will be used to ensure that your order will not be delayed. Should you need assistance identifying the peptide vial that you received, please send us an email at [email protected].

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat and/or cure any medical condition, ailment or disease. Bodily introduction of any kind into animals or human is strictly prohibited by law.